Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2018 / N 2

Выбор лекарственной терапии при дистальной симметричной сенсорно-моторной полиневропатии у больных сахарным диабетом
И.А. Строков, А.С. Фокина, Л.Т. Ахмеджанова, А.В. Зилов, А.Н. Баринов

References

1. Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in Russian Federation: clinical and statistical report according to the Federal diabetes registry. Diabetes Mellitus 2017;20(1):13-41 (In Russian).
2. Shestakova MV, Chazova IE, Shestakova EA. Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease. Diabetes Mellitus 2016;19(1):24-9 (In Russian).
3. Dyck PJ, Davis JL, Litchy WJ, O’Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997 Jul;49(1):229-39.
4. Fokina AS, Strokov IA, Zilov AV. Aktovegin in the treatment of subclinical distal symmetric sensory-motor polyneuropathy in patients with type 2 diabetes mellitus. Medical Council 2016;11:80-5 (In Russian).
5. Dedov II, Shestakova MV, Vikulova OK. National register of diabetes mellitus in Russian Federation, 2014: status and prospects for development. Diabetes Mellitus 2015;18(3):5-22 (In Russian).
6. Strokov IA, Novosadova MV, Barinov AN, Jakhno NN. Clinical methods for assessing the severity of diabetic polyneuropathy. Neurological Journal 2000;5:14-9 (In Russian).
7. Dyck PJ. Diabetic polyneuropathy. In: Diabetic polyneuropathy. Dyck PJ, Thomas PK. editors. 2nd ed. Philadelphia, PA: W.B. Saunders; 1999:255-78.
8. Ziegler D, Papanas N, Zhivov A, Allgeier S, Winter K, Ziegler I, Brüggemann J, Strom A, Peschel S, Köhler B, Stachs O, Guthoff RF, Roden M, German Diabetes Study (GDS) Group. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 2014 Jul;63(7):2454-63.
9. Hovaguimian A, Gibbons CH. Diagnosis and treatment of pain in small fiber neuropathy. Current Pain and Headache Reports 2011 Jun;15(3):193-200.
10. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005 Jun;54(6):1615-25.
11. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Neuromuscular Diseases 2012;2:7-20 (In Russian).
12. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017 Jan;40(1):136-54.
13. Javed S, Alam U, Malik RA. Treating diabetic neuropathy: present strategies and emerging solutions. The Review of Diabetic Studies 2015 Spring-Summer;12(1-2):63-83.
14. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. The Lancet Neurology 2012 Jun;11(6):521-34.
15. Bregovskiy VB, Khramilin VN, Demidova IYu, Strokov IA, Guryeva IV. Distal diabetic polyneuropathy: a review of current recommendations. Annals of Clinical and Experimental Neurology 2015;9(1):60-8 (In Russian).
16. Han Y, Wang M, Shen J, Zhang Z, Zhao M, Huang J, Chen Y, Chen Z, Hu Y, Wang Y. Differential efficacy of methylcobalamin and alpha-lipoic acid treatment on negative and positive symptoms of diabetic peripheral neuropathy. Minerva Endocrinologica 2018 Mar;43(1):11-18. doi: 10.23736/S0391-1977.16.02505-0. Epub 2016 Nov 30.
17. Packer L, Witt EH, Tritschler H. Alfa-lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995 Aug;19(2):227-50.
18. Nagamatsu M, Nickander KK, Schmelzer JD. Raya A, Wittrock DA, Tritschler H, Low PA. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995 Aug;18(8):1160-7.
19. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA. Effect of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism and oxidative stress in experimental diabetic neuropathy. Diabetes 2000 Jun;49(6):1006-15.
20. Strokov IA, Manukhina EB, Bakhtina LYu, Malyshev IYu, Zoloev GK, Kasykhanova SI, Ametov AS.The function of endogenous protective systems in patients with insulin-dependent diabetes mellitus and polyneuropathy: effect of antioxidant therapy. Bulletin of Experimental Biology and Medicine 2000;130(10):437-41 (In Russian).
21. Borcea V, Nourooz-Zadeh J, Wolff SP, Klevesath M, Hofmann M, Urich H, Wahl P, Ziegler R, Tritschler H, Halliwell B, Nawroth PP. α-Lipoic acid decreases oxidative stress in patients with diabetes mellitus. Free Radical Biology & Medicine 1999 Jun;22(11-12):1495-500.
22. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study). Diabetologia 1995 Dec;38(12):1425-33.
23. Ametov AS, Strokov IA, Barinov AN. et al. α-Lipoic acid in the treatment of symptomatic diabetic polyneuropathy: SYmptomatic Diabetic NEuropathY (SYDNEY) trial. Pharmateca 2004;11(88):69-73 (In Russian).
24. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O’Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D; SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid : the SYDNEY trial. Diabetes Care 2003 Mar;26(3):770-6.
25. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy : a critical review. Treatments in Endocrinology 2004;3(3):173-89.
26. Ziegler D, Nowak H, Kempler P. Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with antioxidant α-lipoic acid: a meta-analysis. Diabetic Medicine 2004 Feb;21(2):114-21.
27. Strokov IA, Novosadova MV, Lavrova IN. et al. The prolonged clinical effect of tioctic acid in symptomatic distal diabetic polyneuropathy. In: Proceedings of 14th Annual Scientific Meeting of the Diabetic Foot Study Group and NEURODIAB. Regensburg, Germany; 2004 Sep 02-05; Regensburg, Germany:195.
28. Ziegler D, Reljanovic M, Mehnert H. Gries FA. α-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Experimental and Clinical Endocrinology and Diabetes 1999;107(7):421-30.
29. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006 Nov;29(11):2365-70.
30. Ziegler D, Low PA, Boulton AJM. et al. Effect of a 4-year antioxidant treatment with alpha-lipoic acid in diabetic polyneuropathy: the NATHAN-1 trial. Presented at 67th American Diabetes Association (ADA) Congress, Chicago; 2007 Jun 22-26:abstract 0007-OR.
31. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto DiabeticNeuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010 Oct;33(10):2285-93.
32. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Experimental and Clinical Endocrinology & Diabetes 2008 Nov;116(10):600-5.
33. Mijnhout GS, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? The Netherlands Journal of Medicine 2010 Apr;68(4):158-62.
34. Mijnhout GS, Kollen BJ, Alkhalaf A. Kleefstra N, Bilo HJ. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. International Journal of Endocrinology 2012;2012:456279.
35. Woo YL, Orestes P, Latham J, Naik AK, Nelson MT, Vitko I, Perez-Reyes E, Jevtovic-Todorovic V, Todorovic SM. Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway. The Journal of Neuroscience 2009 Jul;29(30):9500-9.
36. Strokov IA, Fokina AS. α-Lipoic acid as the main pharmacological drug for in- and outpatient treatment of diabetic polyneuropathy. Medical Council 2016;17:28-33 (In Russian).
37. Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009 Aug;32(8):1479-84.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]